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Parkinson’s disease (PD) is characterized by a selective loss of dopamine (DA) neurons
in the human midbrain causing motor dysfunctions. The exact mechanism behind
dopaminergic cell death is still not completely understood and, so far, no cure or
neuroprotective treatment for PD is available. Recent studies have brought attention
to the variety of bioactive molecules produced by mesenchymal stem cells (MSCs),
generally referred to as the secretome. Herein, we evaluated whether human MSCs-bone
marrow derived (hBMSCs) secretome would be beneficial in a PD pre-clinical model,
when compared directly with cell transplantation of hBMSCs alone. We used a
6-hydroxydpomanie (6-OHDA) rat PD model, and motor behavior was evaluated at
different time points after treatments (1, 4, and 7 weeks). The impact of the treatments
in the recovery of DA neurons was estimated by determining TH-positive neuronal
densities in the substantia nigra and fibers in the striatum, respectively, at the end
of the behavioral characterization. Furthermore, we determined the effect of the
hBMSCs secretome on the neuronal survival of human neural progenitors in vitro,
and characterized the secretome through proteomic-based approaches. This work
demonstrates that the injection of hBMSCs secretome led to the rescue of DA neurons,
when compared to transplantation of hBMSCs themselves, which can explain the
recovery of secretome-injected animals’ behavioral performance in the staircase test.
Moreover, we observed that hBMSCs secretome induces higher levels of in vitro neuronal
differentiation. Finally, the proteomic analysis revealed that hBMSCs secrete important
exosome-related molecules, such as those related with the ubiquitin-proteasome and
histone systems. Overall, this work provided important insights on the potential use of
hBMSCs secretome as a therapeutic tool for PD, and further confirms the importance
of the secreted molecules rather than the transplantation of hBMSCs for the observed
positive effects. These could be likely through normalization of defective processes
in PD, namely proteostasis or altered gene transcription, which lately can lead to
neuroprotective effects.
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INTRODUCTION
Parkinson’s disease (PD) represents the second most common
neurodegenerative disorder after Alzheimer’s disease, affecting
∼1% of the population worldwide over 65 years old (Vos
et al., 2017). Its pathogenesis is characterized by the death of
dopamine (DA) neurons in the substantia nigra pars compacta
(SNpc), leading to a decrease of DA levels in the striatum, which
consequently causes typical motor dysfunctions, such as tremor
ate rest, rigidity, bradykinesia, among others (Przedborski, 2017;
Axelsen and Woldbye, 2018). Another important hallmark
feature of PD is the presence of Lewy bodies that are abnormal
aggregates of proteins enriched in α-synuclein (Axelsen and
Woldbye, 2018). Current therapies, such as the administration
of DA analogs or deep brain stimulation, are only focused on
reducing the symptoms but fail to stop disease progression or to
rescue the cells and the neuronal circuit (Anisimov, 2009; Sethi,
2010). On the other hand, stem cell-based therapies have been
providing great opportunities to develop innovative strategies
for PD therapy (Mahla, 2016). Within a variety of promising
cell sources, mesenchymal stem cells (MSCs) have stood out
as a valid therapeutic option (Mendes-Pinheiro, 2016). The
initial research claimed that the engraftment and differentiation
capacity of MSCs was the main responsible mechanism of their
therapeutical effects. However, recent studies brought attention
to the bioactive molecules produced by MSCs, generally referred
to as the secretome (Teixeira et al., 2013; Vizoso et al., 2017).
Among these set of factors/molecules released by MSCs we can
list the soluble proteins (e.g., cytokines, chemokines, and growth
factors), lipids and the extracellular vesicles, that are known
for the capacity of promoting cell survival and differentiation,
prevent neuronal cell death, protect other cells from oxidative
stress or even regulate inflammatory processes (Baraniak and
McDevitt, 2010; Teixeira et al., 2013; Marques et al., 2018).
Previously, we have already shown that human MSCs-bone
marrow derived (hBMSCs) secretome potentiated the increase
of tyrosine hydroxylase (TH)-positive in the SNpc and striatum,
respectively, which supports the improvements observed in
the Parkinsonian animals (Teixeira et al., 2017). In fact, the
use of secretome per se presents numerous advantages when
compared with more conventional stem-cell based applications,
regarding manufacturing, storage, handling, their potential as a
ready-to-use biologic product and lack of immunosuppression-
based adjuvant therapies (Vizoso et al., 2017). For instance,
the time and cost of expansion and maintenance of cultured
MSCs could be significantly reduced, and the storage can be
done for long periods without loss of product potency and
quality (Bermudez et al., 2015, 2016; Vizoso et al., 2017). The
production in large quantities is possible under controlled
laboratory conditions and the biological product could be
modified to desired cell-specific effects (McKee and Chaudhry,
2017; Vizoso et al., 2017). Importantly, the use of the secretome
derivatives could bypass potential issues associated with cell
transplantation including the number of available cells for
transplantation and its survival after this procedure, immune
compatibility, tumorigenicity, and infection transmission
(Tran and Damaser, 2015).
In view of the above, the main objective of this work was to
study the efficacy of hBMSCs secretome when compared to the
traditional approach in the field, that is hBMSCs transplantation,
particularly on DA neurons survival and motor function of
a 6-hydroxydopamine (6-OHDA) rat PD model. Here, we
demonstrate that hBMSCs secretome was able to minimize
the loss of DA neurons and ameliorates the motor deficits of
6-OHDA-lesioned animals. Moreover, we also observed that
hBMSCs were able to induce neuronal differentiation in vitro and
highlighted possible proteins andmechanisms that couldmediate
the above referred actions.
MATERIALS AND METHODS
Human Bone Marrow Mesenchymal Stem
Cells Preparation
hBMSCs (Lonza, Switzerland) were defreeze and plated into T-75
gelatin (0.1%, Sigma, USA)-coated culture flasks with serum-free
growth medium (PPRF-msc6) that was prepared as described
elsewhere in detail (Jung et al., 2010). The medium changes were
done every 3 days, and after reached 80% of confluence, cells
were harvested using 0.05% trypsin/EDTA (Invitrogen, USA)
and plated again in gelatin-coated flasks at a density of 5,000
cells/cm2. For all in vitro experiments, hBMSCs from three
different donors were used. The hBMSCs used in this work were
previously characterized by our lab (Teixeira et al., 2016), being
positive for the standard hMSCs markers CD13, CD73, CD90,
and CD105, and negative for CD34, CD45, and HLA-DR.
Secretome Collection and Concentration
The secretome of hBMSCs was collected under the form of
conditioned medium in passage 5 (P5) according to protocols
already established in our laboratory (Fraga et al., 2013; Teixeira
et al., 2016). Briefly, cells were seeded at a density of 5,000
cells/cm2 for the in vivo experiments and 12,000 cells/cm2
for proteomic analysis. After 3 days in culture, the cells were
washed three times with PBS without Ca2+/Mg2+ (Invitrogen),
and once with Neurobasal-A medium (TermoFisher Scientific,
USA) supplemented with 1% kanamycin (Life Technologies,
USA), being incubated with this medium during 24 h. In
the next day, the medium comprising the elements secreted
by hBMSCs was collected and centrifuged at 1,200 rpm
(Megafuge 1.0R, Heraeus, Germany) for 10min to remove
any cell debris. Then, hBMSCs secretome was concentrated
(100×) by centrifugation using a 5 kDa cut-off concentrator
(Vivaspin, GE Healthcare, UK) and frozen at −80◦C until used
for proteomic analysis and surgical procedures, as previously
described (Mendes-Pinheiro et al., 2018).
Neural Progenitor Cells Growth and
Incubation With hBMSCs Secretome
For neuronal differentiation studies, pre-isolated and
cryopreserved human neural progenitor cells (hNPCs) were
thawed at 37◦C and grew as neurospheres in serum-free medium
PPRF-h2 (Baghbaderani et al., 2010; Mendes-Pinheiro, 2016).
Cells were isolated in respect with the protocols and strict ethical
guidelines previously established and approved by the Conjoint
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 2 November 2019 | Volume 7 | Article 294
Mendes-Pinheiro et al. hBMSCs Secretome in PD Repair
Health Research Ethics Board (CHREB, University of Calgary,
Canada; ID: E-18786) (Mendez et al., 2002, 2005; Baghbaderani
et al., 2010). After 3 days, cells were mechanically triturated to
form single cells and cultivated again in fresh medium. After
14–20 days of growth, hNPCs were enzymatically dissociated and
plated on 24-well plates coated with poly-D-lysine (100µg/mL;
Sigma) and laminin (10µg/mL; Sigma) using 50,000 cells per
well. The cells were exposed for 5 days to hBMSCs secretome, and
supplemented Neurobasal-A medium [differentiation media; 2%
B27 (Gibco, USA), 0.05% basic fibroblast growth factor (bFGF;
R&D Systems, USA), 1% kanamycin, and 0.5% GlutaMAX
(Gibco)] was used as positive control, and Neurobasal-A
medium only with 1% kanamycin (basal media) was used as
negative control group (Mendes-Pinheiro, 2016).
Immunocytochemical Staining
hNPCs were fixed in 4% paraformaldehyde (PFA; Merck,
Portugal) for 30min at room temperature (RT), to retain
the antigenicity of the target molecules and preserve cell
morphology. The permeabilization was done in phosphate
buffered saline (PBS) with 0.1% Triton X-100 (PBS-T; Sigma)
for 5min, followed by blockage of non-specific binding sites
using PBS with 10% newborn calf serum (NBCS; Biochrom,
Germany) for 1 h. hNPCs were then incubated with the following
primary antibodies: anti-doublecortin (DCX, rabbit polyclonal
IgG, 1:300; ab18723, Abcam, UK) for immature neurons and
anti-microtubule associated protein-2 formature neurons (MAP-
2, mouse monoclonal IgG, 1:500; M4403, Sigma), diluted in
PBS with 10% NBCS for 1 h at RT. After washing, cells
were incubated with the secondary antibodies Alexa Fluor 488
goat anti-rabbit (1:1000; Life Technologies) or Alexa Fluor
594 goat anti-mouse (1:1000; Life Technologies) for 1 h at
RT. Nuclei were stained with 4-6-diamidino-2-phenylindole-
dhydrochloride (DAPI, 1:1000; Life Technologies) for 10min
at RT. Afterwards, coverslips were mounted on glass slides
using immu-mount (Thermo Scientific, UK). Finally, samples
were observed using fluorescence microscopy (BX61, Olympus,
Germany), being 3 coverslips per condition and 10 representative
fields chosen for quantification analysis. The overall proportions
of DCX or MAP-2-positive cells in all experiments were pooled
and used for comparison between groups, and the quantification
was done under blind conditions.
Subjects and Surgical Procedures
All animal experimentation was performed with the consent to
the Portuguese national authority for animal research, Direção
Geral de Alimentação e Veterinária (ID: DGAV28421) and
Ethical Subcommittee in Life and Health Sciences (SECVS;
ID: SECVS-008/2013, University of Minho). We used 8-weeks
old Wistar-Han male rats (260–300 g; Charles River, Spain)
that were caged in pairs with food and water ad libitum, in
a temperature/humidity controlled-room maintained on 12 h
light/dark cycles.
All surgical procedures were performed as previously
described by our group (Teixeira et al., 2017; Mendes-Pinheiro
et al., 2018). Succinctly, the PD model was induced by a
unilateral stereotaxic injection of 20mM 6-OHDA dissolved
in saline containing 0.2 mg/mL ascorbic acid. The 6-OHDA
group was injected with 2 µL of 6-OHDA in the right medial
forebrain bundle (MFB; n = 15), and the sham group (n
= 9) received an equal volume of vehicle solution in the
same brain region. Five weeks later, some animals received
hBMSCs transplants and others hBMSCs secretome in the
SNpc and striatum (four different sites), and the groups were
divided as follows: 6-OHDA control group (Neurobasal-A
medium; n = 5), Sham group (sterile saline; n = 9), hBMSCs
transplants (n = 4), and hBMSCs secretome (n = 6). The
6-OHDA-control group received 4 µL of 100× concentrated
Neurobasal-A medium in the SNpc and 2 µL in each coordinate
of striatum. The same volumes and concentrations were
injected in the animals that received hBMSCs secretome. Cell
transplanted groups received 200,000 cells (suspended in serum-
free medium) in SNpc and 200,000 cells in the striatum
divided equally for each coordinate (Mendes-Pinheiro, 2016).
The coordinates used in this work were done according to the
rat brain atlas Paxinos and Watson (2007) as already reported
(Teixeira et al., 2017; Mendes-Pinheiro et al., 2018).
Behavioral Testing
Three weeks after 6-OHDA injections, animals were submitted
to a first behavioral analysis for PD model characterization.
In order to address the impact of hBMSCs transplants or
hBMSCs secretome injections on motor performance of the
animals, behavioral assessment was performed at 1, 4, and 7
weeks after treatments (Figure 1). Firstly, rats were tested in
the rotarod apparatus (3376-4R, TSE systems, USA) to evaluate
their motor coordination and balance as previously described
(Monville et al., 2006). Then, to assess the fine motor control,
the staircase test was performed using the protocol developed by
Montoya et al. (1991).
Last, in order to estimate the dopaminergic denervation and
to select the animals that were truly lesioned upon 6-OHDA
injections, the rotameter test using apomorphine was performed
as previously described (Carvalho et al., 2013).
TH Immunohistochemistry and
Quantification in SNpc and Striatum
To further evaluate the degree of dopaminergic preservation,
immunohistochemical staining for TH was performed. For
that, animals were sacrificed after 13 weeks (including lesion
characterization and behavioral assessment after treatments)
with sodium pentobarbital (Eutasil, 60 mg/kg, i.p.; Ceva Saúde
Animal, Portugal) and perfused through the ascending aorta
with 4% PFA in PBS. Brains were post-fixed in 4% PFA
during 24 h, followed by 30% sucrose in PBS for 1 week.
Coronal striatal and mesencephalon sections were obtained
using a vibratome (VT1000S, Leica, Germany) with 50µm of
thickness. For TH staining, the endogenous peroxidases activity
was stopped in the free-floating sections using 3% hydrogen
peroxidase for 20min at RT, followed by permeabilization in
0.1% PBS-T for 10min (three times) and blockage in PBS
10% NBCS. After this, the sections were incubated with anti-
TH (rabbit polyclonal IgG, 1:2,000; Merck Millipore) overnight
at 4◦C. In the next day, sections were incubated with a
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FIGURE 1 | Design of the in vivo experiments. The animals were unilaterally injected with 6-OHDA directly into the MFB. After 3 weeks, animals were behaviorally
characterized (through rotarod, staircase and rotameter tests) to validate the model. At week 5, 6-OHDA-lesioned animals received hBMSCs transplants or hBMSCs
secretome in the SNpc and striatum. Behavior analysis was performed 1, 4, and 7 weeks after treatments, using the rotarod and staircase tests, and posteriorly
sacrificed to proceed with the histological analysis.
biotinylated secondary antibody (goat anti-polyvalent, TP-
125-BN, ThermoFisher Scientific), followed by strepptavidine-
peroxidase solution (TP-125-HR, ThermoFisher Scientific) for
30min at RT. Antigen revelation was done using of 3,3′-
diaminobenzidine tetrahydrochloride (DAB; D5905, Sigma)
(25mg DAB in 50ml Tris–HCl 0.05M with 12.5 µl H2O2,
pH 7.6). Sections were mounted on slides, and after 24 h
drying in the dark, they were counter-colored with thionin
(Mendes-Pinheiro, 2016).
The estimation of the TH-positive cells’ preservation was done
by counting the total number of DA neurons in the SNpc and
by densitometry analysis of the fibers in the striatum, in both
hemispheres, as already described in detail (Teixeira et al., 2017).
Four slices per animal were randomly chosen for evaluation and
all the analysis was performed under blind conditions. Data is
presented as the percentage (%) of remaining TH-positive cells
in the lesioned side compared to the control side (intact side) for
both regions.
Untargeted Mass Spectrometry Proteomic
Analysis
In order to characterize the hBMSCs secretome we performed
a non-targeted proteomic analysis based on a combined mass
spectrometry (MS) approach as previously described (Mendes-
Pinheiro et al., 2018). Only proteins with at least two confidently
identified peptides were considered as positive identifications.
Peptide’s confidence was assessed by a False Discovery Analysis
(FDR) and a minimum of 99% confidence (<1% FDR)
was used to select the peptides. Three biological replicates
of secretome were processed, and proteins that were just
identified in a single biological replicate were not considered
for analysis. The MS proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE (Perez-
Riverol et al., 2019) partner repository with the dataset identifier
PXD014887. The final list of proteins (Supplementary Material)
was used for gene ontology characterization (levels 2 and
3) using PANTHER (Mi et al., 2013), regarding molecular
function, protein class and signaling pathways. A levels 4 and
5 gene ontology analysis was performed through an over-
representation analysis using the ConsensusPathDB (Kamburov
et al., 2013), for molecular function. Protein complex-based
gene sets were determined using the same software, and
assuming a minimum complex size of 2, minimum overlap
with input list of 2, and p-value cutoff of 1%. The two most
represented protein complexes are shown, based on the p-value
for association.
Statistics
A confidence interval of 95% was assumed for all statistical
tests. The assumption of normality was tested for all continuous
variables through evaluation of the frequency distribution
histogram, the values of skewness and kurtosis and through
the Shapiro-Wilk test. The assumption of homoscedasticity
was tested through Levene’s test. Both assumptions were met
by all tested continuous variables. All continuous data is
shown as the mean as mean ± SEM. For the comparison
of proportions between different groups, a Chi-square test
was performed, followed by a z-test for the comparison of
independent proportions with the Bonferroni correction. For
the comparison of means between two groups, a Student’s
t-test for independent samples was used, when data was
continuous; for discrete data, a Mann-Whitney U test was
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carried out. For the evaluation of mean differences in samples
with one independent and one repeated measures variable,
a mixed design ANOVA was carried out, with Tukey’s post-
hoc test for pairwise comparison of the independent variable.
Statistical analysis was performed using IBM SPSS Statistics
ver.24 (IBM Co., USA) and graphic representation using
GraphPad Prism ver.7.0c (GraphPad Software; La Jolla, USA).
RESULTS
Effects of hBMSCs Secretome on Neuronal
Differentiation in vitro
hNPCs grow as neurospheres in the presence of PPRF-h2
serum-free medium as previously described (Baghbaderani
et al., 2010; Teixeira et al., 2015). Typically, upon removal
of their growth medium hNPCs lose their neurosphere-
like conformation, adhere and spontaneously start to
differentiate. The differentiation of hNPCs was further
confirmed by immunocytochemistry analysis for DCX
and MAP-2, after 5 days in culture, staining for immature
and early stage mature neurons, respectively. As expected,
hNPCs with basal media (negative control) were unable
to differentiate, while cells with differentiation medium
(positive control) showed positive differentiation for both
MAP-2 and DCX neurons (Figures 2A–D). Interestingly,
the hBMSCs secretome was also able to increase the
proportion of differentiated neurons, as shown by an
increase in MAP-2 staining, similar to differentiation
rates of standard neuronal differentiation media-treated
cells (Figures 2E–H).
Injection of hBMSCs Secretome
Attenuates the Fine Motor Deficits of
6-OHDA-Lesioned Animals
Three weeks after 6-OHDA injections into the MFB (Figure 3A),
rats were behaviorally characterized in order to evaluate PD-like
symptoms. To access the motor function of the animals, rotarod
and the staircase tests were performed. Motor coordination
and balance, assessed by the rotarod test, was found to be
impaired in animals injected with 6-OHDA (Figure 3B). In
the staircase test, performed to assess the forelimb use and
skilled motor function, it was also observed that the 6-OHDA-
injected animals were significantly affected when compared
to sham animals (Figure 3C). To evaluate the level of DA
depletion the rotameter test was performed at the end of
rotarod and staircase tests, and an intense turning behavior
after apomorphine administration was observed in 6-OHDA-
injected animals when compared with sham group (Figure 3D)
(Mendes-Pinheiro, 2016). Then, to address the effects of either
hBMSCs transplants or hBMSCs secretome injections, as well
as comparing both treatments, the motor performance of
the animals was evaluated in three different time-points after
treatments (1, 4, and 7 weeks) following the same timeline as
previsouly reported elsewhere (Teixeira et al., 2017; Mendes-
Pinheiro et al., 2018). Regarding the rotarod test, motor
coordination and balance of the 6-OHDA-lesioned animals was
unchanged upon hBMSCs cell transplantation or secretome
administration (Figure 4A). On the other hand, in the staircase
test, used to assess the fine motor movements, animals treated
with hBMSCs secretome showed a significant increase in the
success rate of eaten pellets when compared to the untreated
group (Figure 4B). Moreover, the treatment with hBMSCs
FIGURE 2 | Effect of hBMSCs secretome in the differentiation of hNPCs in vitro. (A–C) Representative microphotographs of DCX staining in hNPCs and (D)
respective quantification of the proportion of stained cells, as marker of immature neurons [Chi-squared, χ2(2) = 79.862, p < 0.0001]. A total number of 1,906 cells
were scored for the negative control and a minimum of 13,000 for the other conditions, across two independent experiments. (E–G) Representative
microphotographs of MAP-2 staining in hNPCs and (H) respective quantification of the proportion of stained cells, as a marker of mature neurons. A total number of
1,620 cells were scored for the negative control, and a minimum of 23,000 for the other conditions, across two independent experiments [Chi-squared, χ2(2) =
113.367, p < 0.0001]. Nuclei were stained with DAPI. ***p < 0.0001 (Scale bar: 100 µm).
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transplants was not able to improve the motor function of the
animals in the staircase test when compared to the untreated
group (Figure 4B).
Injection of hBMSCs Secretome Protects
Against TH Damage in SNpc and Striatum
After histological analysis in the SNpc and striatum, we
observed that the treatment with hBMSCs secretome was
able to signifcantly minimize the dopaminergic loss upon 6-
OHDA administration, which was not verified with hBMSCs
transplanted group. In fact, TH staining revealed a significantly
higher number of TH-positive cells in the SNpc when compared
to the untreated group 6-OHDA (Figures 5A–E). Likewise, the
same difference in the striatumwas observed, bymeasuaring TH-
positive fibers through densytometry analysis (Figures 5F–J).
These finding are particularly important since they were obtained
with a one-time administration of hBMSCs secretome, which
produced effects over the course of the following 7 weeks.
Moreover, it also important to highlight the differences obtained
when compared to the hBMSCs cell transplanted group, which
has been considered for many years one of the go-to strategies in
stem cell base approaches for PD regenerative medicine.
Characterization of Protein Sets That
Constitute the Secretome of hBMSCs
Secretome
To identify potential therapeutic molecules in the hBMSCs
secretome that could be involved in the strong response of the
secretome-injected animals, the latter was characterized through
a non-biased proteomic analysis based on a combined mass
spectrometry (MS) approach (Mendes-Pinheiro, 2016). We were
able to identify 279 proteins (according to the UniProtKB/Swiss-
Prot classification) in the hBMSCs secretome, common to
all replicates, from which 426 were detected based on 2 or
more peptides, and therefore used in further analyses. An
initial gene ontology analyses (levels 2 and 3) was carried
out using PANTHER, in order to broadly characterize the
protein types presented in the hBMSCs secretome. Regarding
molecular function, more than 80% of identified proteins were
either allocated in the binding or catalytic activity categories
(Figure 6A), which is in accordance with the fact that this is
a secreted media (Teixeira et al., 2016; Mendes-Pinheiro et al.,
2018). In agreement, classification by protein class revealed
that hydrolases and enzyme modulators were in the top three
categories (Figure 6B). Regarding the signaling pathways that
are mostly represented in the secretome, Parkinson’s disease-
related proteins was one of the top categories (Figure 6C),
which suggests that the secretome contains protein elements
that might be beneficial for PD context. A more detailed
gene ontology analysis (levels 4 and 5) was then performed
using the ConsensusPathDB. Interestingly, the most represented
category of cellular components observed was extracellular
exosomes (Figure 6D). When it comes to the mostly represented
protein complexes, we identified elements from the proteasome
(Figure 6E) and from histones (Figure 6F) as enriched in
the secretome. This analysis provides interesting clues on the
relevance of the composition of hBMSCs secretome in the
context of PD.
DISCUSSION
The main goal of this study was to determine the impact of the
injection of the secretome-derived from hBMSCs as a potential
therapy for PD, when compared to what is considered the current
gold standard in the field of cell-based therapies for regenerative
medicine, that is the stem cell-based transplantation approaches.
PD is characterized by an extensive loss of DA neurons in the
SNpc and their terminals in the striatum, resulting in debilitating
motor problems (Przedborski, 2017). Therefore, in the in vivo
experiments, in order to cause dopaminergic degeneration, was
used a rat PD model induced by 6-OHDA injection into the
MFB (Carvalho et al., 2013; Mendes-Pinheiro, 2016). As in line
with previous reports (Teixeira et al., 2017; Mendes-Pinheiro
et al., 2018), here we were able to successfully establish the
model. As shown in the rotameter test (Figure 3D), 6-OHDA-
lesioned animals displayed a strong turning behavior when
compared to the sham group (injected with saline), indicating a
clear magnitude of the lesion. We also verified that the motor
function of these animals was affected, since they presented
deficits in motor coordination and balance, as well as in the
skilled motor function, addressed by the rotarod and staircase
tests, respectively (Figures 3B,C). Regarding the effects of the
treatments, we observed that neither the hBMSCs transplants
nor secretome injections were able to improve the animals’
motor coordination and balance in the rotarod test (Figure 4A).
It is important to state that the rotarod test is commonly
used in this context, however, it has also been described that
is not the most sensitive test to use in models that present
basal ganglia dysfunctions (Magen and Chesselet, 2010; Mann
and Chesselet, 2014). Moreover, since we used the accelerating
protocol during 4 consecutive days (4 trials per day), the fatigue
of the animals could explain in part the results obtained. On
the other hand, the fine motor skill task has been used in
different models of PD, and it was shown to be very suitable
to detect striatum/nigrostriatal bundle unilateral lesions (Baird
et al., 2001). Indeed, when the forelimb reaching and grasping
abilities were assessed using the staircase test, we observed
that the injection of hBMSCs secretome improved the success
rate of eaten pellets of the treated animals when compared to
the untreated group 6-OHDA (Figure 4B). Additionally, rats
injected with hBMSCs secretome showed better preservation in
the number of TH-positive neurons in the SNpc, as well as
an increase in the density of TH-positive fibers in the striatum
(Figure 5). These histological outcomes nicely correlate with
positive functional improvements that we observed in the fine
motor movements for the animals treated with secretome. On
the other hand, such evidences were not observed in hBMSCs-
transplanted animals, probably due to the low survival rate
of cells upon transplantation. We performed human nuclear
antigen staining for hBMSCs detection (data not shown), and we
were not able to observe the presence of the grafts on both SNpc
and striatum. In fact, it has been shown that the MSCs survival
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FIGURE 3 | PD model validation. (A) Animals received a unilateral injection of 6-OHDA into the MFB in order to induce PD-like symptoms. (B) Latency to fall was
measured in the accelerating rotarod test, demonstrating that 6-OHDA-injected animals presented significant motor impairment in motor coordination and balance
[Student’s t-test, t(19) = 3.849, p < 0.01, Sham: n = 7, 6-OHDA: n = 14]. (C) Deficits in forelimb use and skilled motor function were also observed after the staircase
test evaluation [Mixed design ANOVA, Fgroup (1,22) = 76.290, p < 0.0001, Sham: n = 9, 6-OHDA: n = 15]. Data is presented as mean ± SEM. (D) Rotameter test
revealed that 6-OHDA-injected animals exhibited an intense turning behavior, showing a clear decline of the dopaminergic system (Mann-Whitney, U = 0, p < 0.0001,
Sham: n = 9, 6-OHDA: n = 15). Data is presented as median ± IQR. **p < 0.01, ***p < 0.001.
is minimal and the implantation time of these cells is usually too
short to have an effective impact (Vizoso et al., 2017).
In the past few years MSCs has been widely studied as
therapeutical agents in different pathological conditions of the
central nervous system (CNS), including PD (Teixeira et al.,
2013; Salgado et al., 2015; Konala et al., 2016). Primary studies
showed that transplanted MSCs were able to repair injured
adult mesenchymal tissues; thereafter, some authors also reported
the capacity of MSCs to transdifferentiate into ectodermal-
derived cells (Donega et al., 2014; Takeda and Xu, 2015;
Bagher et al., 2016). While these studies were accompanied
with some controversy throughout the years, robust data
have been demonstrating that the paracrine activity of MSCs
could have a critical role in its beneficial effects. In fact,
MSCs are able to secrete a wide spectrum of elements with
strong immunomodulatory properties, which are also able to
inhibit apoptosis, enhance angiogenesis and promote neuronal
survival and differentiation (Marote et al., 2016). This is the
first study comparing directly hBMSCs secretome injections
with hBMSCs transplantation. Nonetheless, other authors
correlated motor improvements and DA neurons’ protection
with the secretion and local increase of different growth factors
after MSCs transplantation (Sadan et al., 2009; Cova et al.,
2010; Wang et al., 2010; Cerri et al., 2015), supporting the
secretome theory.
To explore the possible underlying mechanisms or key
molecules behind the secretome effects, we characterized the
latter using a MS proteomic approach. Interestingly, when we
evaluated cellular components at a more detailed level, we
observed a very large enrichment of proteins that are part
of exosomes. Moreover, this category of proteins was clearly
overrepresented when compared with the other top hits. In
fact, some studies demonstrate that the administration of MSCs-
derived exosomes was able to rescue tissue function in different
disease/injury contexts and to induce beneficial in vitro effects,
mainly mediated by exosomal-enclosed microRNAs (miRNAs)
(Marote et al., 2016; Vilaça-Faria et al., 2019). For instance,
Jarmalavičiute et al. (2015), using a 6-OHDA 3D culture model,
showed that dental pulp MSCs-derived exosomes rescue DA
neurons from cell death. Hence, the beneficial effects of the
hBMSCs secretome that observed in this work could be mediated
by a similar exosome-dependent mechanism. Additionally, other
studies demonstrated the potential of exosomes produced by
MSCs on neuronal differentiation. For instance, Lee et al.
(2014) showed that BMSCs had the capacity to the deliver
miRNAS, namely miR-124 and miR-145, to NPCs and astrocytes,
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FIGURE 4 | Effects of hBMSCs transplants and hBMSCs secretome injections on the motor performance of 6-OHDA-lesioned animals at 1, 4, and 7 weeks after
treatments. (A) No differences were found in the 6-OHDA-lesioned animals’ motor coordination and balance after hBMSCs secretome administration [Mixed design
ANOVA, FGroup (3,17) = 28.875, p < 0.0001, Sham: n = 7, 6-OHDA: n = 5, hBMSCs: n = 4, hBMSCs secretome: n = 5]. (B) In the staircase test, used to evaluate
the fine motor movements, animals treated with hBMSCs secretome showed a significant increase in the success rate of eaten pellets when compared to the
untreated group 6-OHDA [Mixed design ANOVA, FGroup (3,20) = 22.804, p < 0.0001, Sham: n = 9, 6-OHDA: n = 5, hBMSCs: n = 4, hBMSCs secretome: n = 6].
Data is presented as mean ± SEM. *p < 0.05; Sham animals statistically different from all the other groups: #p < 0.0001.
FIGURE 5 | Injection of hBMSCs secretome protects against DA neurons damage. (A–E) The TH-positive cells were counted in the entire SNpc, and we observed
that hBMSCs secretome injections was able to minimize the TH loss when compared to the untreated group 6-OHDA [One-way ANOVA, F (3, 23) = 84.541, p <
0.0001, Sham: n = 9, 6-OHDA: n = 5, hBMSCs: n = 4, hBMSCs secretome: n = 6]. (F–J) The same effect was also detected in the striatum, by measuring
TH-positive fibers through densitometry analysis [One-way ANOVA, F (3, 20) = 110.564, p < 0.0001, Sham: n =6, 6-OHDA: n = 5, hBMSCs: n = 4, hBMSCs
secretome: n = 6]. Data is presented as mean ± SEM. *p < 0.05; Sham animals statistically different from all the other groups: #p < 0.0001.
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FIGURE 6 | Gene ontology analyses of the identified proteins in a proteomic analysis of the hBMSCs secretome from three independent donors. Categorization of the
most represented (A) molecular functions, (B) protein classes, and (C) signaling pathways, using the PANTHER software (gene ontology levels 2 and 3). Results are
shown as the percentage of proteins that are part of each individual GO category. Categorization of the enrichment of (D) cellular components, (E) elements of the
proteasome and (F) elements of histones, using the ConsensusPathDB software (gene ontology levels 4 and 5). Results are shown as the –log of the p-value for the
enrichment of each individual category.
impacting cell differentiation and increasing the expression
of glutamate transporters. Another study, exposing cortical
neurons to MSCs-derived exosomes, showed an improvement
in neurite outgrowth, by increasing both neurite branch and
total length, and attributing the effects to the transference of
miR-133b to neural cells (Xin et al., 2012). Similarly, Lopez-
Verrilli et al. (2016), showed that menstrual MSCs-derived
and BMSCs exosomes promote neurite growth in cortical
neurons and dorsal root ganglia neurons, respectively. This is
also in line with our results, since secretome-treated hNPCs
showed and increase proportion of MAP-2 staining. Moreover,
another interesting study using a 6-OHDA mice PD model,
reported that mimic-miR-124 increased neurogenesis in the
subventricular zone (SVZ) which was correlated with significant
behavioral improvements (Saraiva et al., 2016). Altogether,
this evidence indicates that besides dopaminergic survival, the
modulation of neurogenesis may also have influence in the
recovery of PD, and could be one of the reasons behind the
observed secretome-effects.
The precise cause of PD remains elusive, but compelling
evidence spotlight the ubiquitin proteasome system (UPS) as
a key feature in PD pathogenesis (Bentea et al., 2017). This
connection was supported due to genetic mutations in the
PRKN and UCHL1 genes, with critical roles in the UPS system,
with familial parkinsonism (Kitada et al., 1998; Summers et al.,
1998). In this follow up, McNaught et al. (2001) observed a
significant decrease of proteasomal core subunits in the SN of
sporadic PD brains. Furthermore, some studies showed that
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proteasomal inhibitors like lactacystin and proteasome inhibitor
1 (PSI) leads to dopaminergic cell death in vitro and after brain
injections (McNaught et al., 2002a,b; Matsui et al., 2010; Xie
et al., 2010). Although it is not part of the UPS, overexpression
of wild-type or mutant α-synuclein both in vitro and in vivo
was also shown to impede proteasome function (Stefanis et al.,
2001; Tanaka et al., 2001; Chen et al., 2006). With UPS
dysfunction being one of the pathophysiological hallmarks of
PD, and since one of more enriched protein networks in the
hBMSCs secretomewas the proteasome, we can speculate that the
restoration of UPS-dependent proteostasis could be one of the
main mechanism responsible for the phenotypical improvement
we observed.
Finally, we also observed that histones are one of the mostly
represented protein complexes in hBMSCs secretome. Indeed,
histone modifications have been linked with the development,
differentiation and maintenance of DA neurons (van Heesbeen
et al., 2013). Park and co-workers (Park et al., 2016) demonstrated
an increase of histone acetylation in DA neurons of PD patients
when compared to healthy individuals. Besides that, using the
MPTP model both in vitro and in vivo, the same authors
showed a decrease of multiple histone deacetylases (HDACs),
as well as in the midbrain tissues of human PD patients (Park
et al., 2016). In cellular models, either dieldrin or paraquat
were shown to induce histone acetylation (Song et al., 2010,
2011). In addition, Goers et al. (2003) showed in culture
an interaction between histones and α-synuclein via complex
formation, as well as, that α-synuclein fibrillation was intensely
enhanced in the presence of histones. Another study, using
two different PD models, demonstrated that DA reduction
and following levodopa treatment were related with intense
alterations in post-translational modifications histones in the
striatum (Nicholas et al., 2008). Altogether, these findings suggest
that chromatin remodeling may have an important role in
PD pathogenesis.
Additionally, previous work from our already showed that
hBMSCs is a source of numerous neuroregulatory molecules
with neuroprotection character (Pires et al., 2016). For instance,
similarly to the above referred work, we found in our proteomic
analysis, important proteins known as anti-oxidant agents, such
as DJ-1, TRXR1, and PRDX1 that have been shown to counteract
dopaminergic cell death in different PD models as reviewed by
Pires et al. (2016). Also PEDF, it is known for its neurotrophic
properties but also for neuroprotective roles in different PD
toxin models (Falk et al., 2009). This neuroprotective effects
have been linked to the capacity for induce the activation of
nuclear factor NF-κB signaling cascade, which in turn induces the
expression of genes that are essential to neuronal protection and
survival, such as BDNF and GDNF (Falk et al., 2010). Moreover,
other proteins like Galactin-1 and Cystatin C have also been
associated with anti-apoptotic effects in in vitro models of PD
(Pires et al., 2016).
Although candidate molecules and possible mechanisms are
under investigation, further detailed studies are needed to
carefully define which playersmay be responsible for the hBMSCs
secretome-mediated effects. In the future, we intend to conduct
studies, both in vitro and in vivo, regarding the identification of
some of these molecules and their roles in the context of PD.
In conclusion, the present findings support hBMSCs secretome
treatment as a novel therapeutic strategy for PD. Moreover,
we have also shown that its application in a well-described
rat model of PD is more effective than the traditional cell
transplantation approaches, which have been considered one
of the most preferred strategies in the field of stem cell-based
PD regenerative medicine for several years. However, additional
work is still necessary in order to improve the applicability of
this approach.
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